Aquestive Therapeutics Inc

Stage 2 advancing remains intact despite the late‐June exhaustion signal. Price has retraced into the rising 9/21/50 EMA confluence on neutral RSI and OB/OS context, offering a disciplined entry. Speculative intent favors buying this pullback while preserving the uptrend and monitoring for an EMA breach.

• ↑Positive Anaphylm PK/usability studies bolster FDA approval prospects.
• ↑Q2 revenue $13.82M (+18% YoY) with FY guidance of $46–50M.
• ↓Net loss $22.9M in Q2 highlights persistent cash burn.